altepláza

Altepláza is a medication also known as tissue plasminogen activator (tPA). It is a thrombolytic drug, meaning it is used to break down blood clots. Altepláza works by activating plasminogen, a protein in the blood, which then converts into plasmin. Plasmin is an enzyme that degrades fibrin, a major component of blood clots. By dissolving these clots, altepláza can restore blood flow to tissues that have been deprived of it.

The primary use of altepláza is in the treatment of acute ischemic stroke. When administered within a specific time window after the onset of stroke symptoms, it can significantly improve outcomes by reducing the extent of brain damage. Altepláza is also used to treat myocardial infarction (heart attack) in certain situations, particularly when angioplasty is not readily available. Additionally, it can be used to clear clots from central venous catheters.

Administration of altepláza requires careful medical supervision due to the risk of bleeding, which is a significant side effect. The decision to use altepláza is based on a careful assessment of the patient's condition, the timing of symptom onset, and the potential benefits versus risks. It is typically given intravenously.